FIELD: medicine; pharmacology.
SUBSTANCE: invention concerns new compositions containing: (a) GLP-1 compound selected out of a group including GLP-1 compounds represented in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9, SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14; and (b) transport medium selected out of a group including transport media 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55 and 56. These compositions enable easy GLP-1 compound absorption by peroral administration, thus allowing peroral administration of GLP-1 compound, omitting multiple injections.
EFFECT: improved efficiency of the composition and treatment method.
18 cl, 9 ex, 4 tbl, 22 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| TREATMENT OF NEUROLOGICAL DISEASES | 2017 |
|
RU2755997C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
